Shares of Alkermes ALKS rose 2.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 33.33% year over year to $0.06, which beat the estimate of ($0.01).
Revenue of $247,529,000 decreased by 11.56% from the same period last year, which beat the estimate of $232,750,000.
Outlook
The upcoming fiscal year's EPS expected to be between $0.00 and $0.19.
The upcoming fiscal year's revenue expected to be between $965,000,000 and $1,005,000,000.
How To Listen To The Conference Call
Date: Jul 29, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/vx5ij3ka
Recent Stock Performance
52-week high: $23.50
Company's 52-week low was at $11.98
Price action over last quarter: Up 47.19%
Company Description
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
